MicroPort Scientific : First Indian Rate Contract Kicks Off in 2017

India, New Delhi- On January 4, MicroPort Scientific India Private Limited ('MicroPort Scientific India'), the Indian subsidiary of MicroPort Scientific Corporation ('MicroPort Scientific'), announced that it successfully got the first annual rate contract for its innovative Firehawk Rapamycin Target Eluting Coronary Stent System ('Firehawk') from Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, an Institute of National Importance under the Department of Science and Technology, Government of India.

Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum is a prestigious Indian government hospital that offers advanced treatment using modern technologies in several specialized areas such as interventional radiology, cardiac electrophysiology, deep brain stimulation for movement disorders, epilepsy surgery, pediatric cardiac surgery, base of skull and vascular surgeries, to name a few. The institute has excellent facilities and teams of professionals dedicated to the development of innovative biomedical devices and products, evaluation of medical devices to global specifications, training in novel medical specialties and research in medical and public health areas of social relevance.

Founded on August 11, 2016, the Indian subsidiary aims to serve the Indian patients with high-quality research-based medical solutions at affordable prices. Its first Indian rate contract means the innovative product Firehawk™ was recognized by Indian experts and will earn a place in the India market.

'India is one of the most important strategic markets for MicroPort Scientific, and we are extremely pleased to see our star product Firehawk recognized by local experts,' said Dr. Linda Lin, Vice President of International Business. 'By constant endeavor of the whole team, we believe our products will benefit more overseas patients.'

Mr. Riyaz Desai, Managing Director of MicroPort Scientific India, said: 'As a new member of MicroPort Scientific, the Indian subsidiary aims to serve the Indian patients with high-quality research-based medical solutions at affordable prices. MicroPort is committed to save and reshape many lives and improve quality of life of Indian patients. This first rate contract from a prestigious Indian government hospital signifies an auspicious start of business development of MicroPort in Indian market'.

India has the third largest amount of PCI cases in the world, and the market is experiencing rapid development in recent years. The first rate contract from a famous local government hospital marks a good beginning of market expansion of MicroPort Scientific in India, to bring more ideal solutions to Indian patients who suffer from cardiovascular diseases.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:

Sophie Wei Senior Corporate Culture Manager Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-8018 Email: [e-mail]